Tesofensine 500mcg Tablets | 100-Count
🇺🇸 1-Region Domestic Shipping
QSC Tesofensine (triple reuptake inhibitor — DA/5HT/NE) — ≥99% HPLC purity, MS confirmed, Janoshik COA. Research use only.
* The information on this page is a summary and is not intended to cover all available information about this medication. It does not cover all possible uses, directions, precautions, drug interactions or adverse effects and is not a substitute for the expertise and judgement of your healthcare professional.
{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “How are QSC research tablets supplied?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “QSC research tablets are supplied as pre-dosed oral tablets at the stated concentration. No reconstitution is required. Each tablet is compressed at uniform dose for consistent dosing in research applications.”}}, {“@type”: “Question”, “name”: “How should research tablets be stored?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Store at room temperature (15–25°C) in a cool, dry place away from moisture, heat, and direct sunlight. Keep in the original container. Properly stored tablets remain stable for 2–3 years.”}}, {“@type”: “Question”, “name”: “What purity are QSC research tablets and how is it verified?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “QSC research tablets contain active ingredient at ≥99% HPLC purity before tableting, with MS-confirmed identity on every batch. COA is published on the product page and independently verifiable at verify.janoshik.com.”}}]}
What is Tesofensine?
Tesofensine is a triple monoamine reuptake inhibitor — simultaneously blocking DAT, SERT, and NET. Originally developed for Parkinson’s and Alzheimer’s, it demonstrated exceptional appetite suppression and weight loss in Phase 2 obesity trials. Phase 2 (2008): 10.6% body weight reduction at 0.5mg/day over 24 weeks. CAS 195875-84-4.
Research Applications
Triple Reuptake Inhibition
DAT/SERT/NET — hypothalamic appetite circuit modulation
Obesity Pharmacology
Phase 2: 10.6% weight reduction — comparison vs GLP-1R class
Monoamine Neuroscience
DA/5HT/NE selectivity and occupancy studies
Energy Expenditure
Sympathomimetic thermogenesis — BAT activation
Addiction Research
Dopamine reuptake inhibition — reward pathway pharmacology
Quick Specs
| Form | Tablet — 500mcg per tablet, 100-tablet bottle |
| CAS Number | 195875-84-4 |
| Molecular Formula | C₁₇H₂₃ClN₂O |
| Molecular Weight | 322.8 g/mol |
| Compound Type | Triple Monoamine Reuptake Inhibitor |
| Purity | ≥99% by HPLC — every batch |
| Identity | MS molecular weight confirmed — every batch |
| COA | Janoshik-independent, publicly verifiable |
| Manufacture | In-house synthesis — Qingdao, China |
| Storage | Room temperature sealed | cool, dry storage |
| Shelf Life | 24 months unopened |
Certificate of Analysis (COA)
Frequently Asked Questions
Frequently asked questions
A seemingly elegant design can quickly begin to bloat with unexpected content or break under the weight of actual activity. Fake data can ensure a nice looking layout but it doesn’t reflect what a living, breathing application must endure. Real data does.
Websites in professional use templating systems. Commercial publishing platforms and content management systems ensure that you can show different text, different data using the same template. When it’s about controlling hundreds of articles, product pages for web shops.
A seemingly elegant design can quickly begin to bloat with unexpected content or break under the weight of actual activity. Fake data can ensure a nice looking layout but it doesn’t reflect what a living, breathing application must endure. Real data does.
Websites in professional use templating systems. Commercial publishing platforms and content management systems ensure that you can show different text, different data using the same template. When it’s about controlling hundreds of articles, product pages for web shops.
Reviews
Clear filtersThere are no reviews yet.